Cartesian TherapeuticsRNAC
RNAC
About: Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
Employees: 38
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
21% more capital invested
Capital invested by funds: $90.9M [Q2] → $110M (+$19.4M) [Q3]
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
9.82% more ownership
Funds ownership: 18.93% [Q2] → 28.75% (+9.82%) [Q3]
3% more funds holding
Funds holding: 62 [Q2] → 64 (+2) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$41
122%
upside
Avg. target
$43
131%
upside
High target
$45
144%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
BTIG Julian Harrison 33% 1-year accuracy 6 / 18 met price target | 127%upside $42 | Buy Initiated | 19 Dec 2024 |
HC Wainwright & Co. Mitchell Kapoor 25% 1-year accuracy 41 / 163 met price target | 144%upside $45 | Buy Reiterated | 4 Dec 2024 |
Needham Gil Blum 18% 1-year accuracy 29 / 164 met price target | 122%upside $41 | Buy Reiterated | 3 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On December 12, 2024, the Company issued to these employees options to purchase an aggregate of 25,602 shares of the Company's common stock with an exercise price of $20.12, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on December 12, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on December 12, 2028. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
Neutral
GlobeNewsWire
3 weeks ago
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points at Month 4 relative to placebo
Neutral
GlobeNewsWire
1 month ago
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
Company to host conference call and webcast with key opinion leader on December 3, 2024, at 7:30 a.m. ET Company to host conference call and webcast with key opinion leader on December 3, 2024, at 7:30 a.m. ET
Negative
Seeking Alpha
1 month ago
Cartesian Therapeutics: Uncertainty Remains
Cartesian Therapeutics' stock has rebounded sharply recently despite no significant news, driven partly by insider buying after a disappointing Phase 2b trial for Descartes-08 in myasthenia gravis. The company leverages its RNA Armory platform for mRNA cell therapies, focusing on autoimmune diseases, with Descartes-08 and Descartes-15 as its main assets. Descartes-08 showed mixed results in Phase 2b for MG, raising concerns due to endpoint changes and trial anomalies, yet plans continue for a pivotal trial in 2025.
Neutral
GlobeNewsWire
1 month ago
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to two new employees. On November 4, 2024, the Company issued to these employees options to purchase an aggregate of 4,854 shares of the Company's common stock with an exercise price of $19.11, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on November 4, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on November 4, 2028. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
Negative
Zacks Investment Research
1 month ago
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates
Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $2.40 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end
Negative
24/7 Wall Street
2 months ago
Insider Buying Slows, but Not for 7 These Buyers
24/7 Wall St. Insights Insider buying slowed to a trickle ahead of the third-quarter earnings reporting season.
Positive
Zacks Investment Research
2 months ago
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?
Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
GlobeNewsWire
2 months ago
Cartesian Therapeutics Announces New Employment Inducement Grants
GAITHERSBURG, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On October 1, 2024, the Company issued to these employees options to purchase an aggregate of 60,961 shares of the Company's common stock with an exercise price of $17.11, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on October 1, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on October 1, 2028. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
Charts implemented using Lightweight Charts™